| Dr Ryan Hoff, | |
|
505 Ne 87th Ave Ste 301, Vancouver, WA 98664-1965 | |
| (360) 514-7060 | |
| (360) 514-7068 |
| Full Name | Dr Ryan Hoff |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 10 Years |
| Location | 505 Ne 87th Ave Ste 301, Vancouver, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841612439 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 036.141540 (Illinois) | Secondary |
| 207RG0100X | Internal Medicine - Gastroenterology | OP61131025 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Peacehealth Southwest Medical Center | Vancouver, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Peacehealth | 8820178288 | 169 |
| Peacehealth | 9739092065 | 86 |
News Archive
USC researchers have pinpointed a remedy to thwart a protein that helps the metastatic spread of breast cancer, a leading cause of death for women. The findings appear today in Nature Communications.
The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.
A single gene called cylE within the important bacterial pathogen Group B Streptococcus (GBS), controls two factors that act together as a "sword" and "shield" to protect the bacteria from the killing effects of the immune system's white blood cells
› Verified 8 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134178999 PECOS PAC ID: 9739092065 Enrollment ID: O20031111000831 |
News Archive
USC researchers have pinpointed a remedy to thwart a protein that helps the metastatic spread of breast cancer, a leading cause of death for women. The findings appear today in Nature Communications.
The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.
A single gene called cylE within the important bacterial pathogen Group B Streptococcus (GBS), controls two factors that act together as a "sword" and "shield" to protect the bacteria from the killing effects of the immune system's white blood cells
› Verified 8 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609061969 PECOS PAC ID: 8820178288 Enrollment ID: O20080110000429 |
News Archive
USC researchers have pinpointed a remedy to thwart a protein that helps the metastatic spread of breast cancer, a leading cause of death for women. The findings appear today in Nature Communications.
The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.
A single gene called cylE within the important bacterial pathogen Group B Streptococcus (GBS), controls two factors that act together as a "sword" and "shield" to protect the bacteria from the killing effects of the immune system's white blood cells
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ryan Hoff, 505 Ne 87th Ave Ste 301, Vancouver, WA 98664-1965 Ph: (360) 514-7060 | Dr Ryan Hoff, 505 Ne 87th Ave Ste 301, Vancouver, WA 98664-1965 Ph: (360) 514-7060 |
News Archive
USC researchers have pinpointed a remedy to thwart a protein that helps the metastatic spread of breast cancer, a leading cause of death for women. The findings appear today in Nature Communications.
The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.
A single gene called cylE within the important bacterial pathogen Group B Streptococcus (GBS), controls two factors that act together as a "sword" and "shield" to protect the bacteria from the killing effects of the immune system's white blood cells
› Verified 8 days ago
Kanuboddu Nagarjuna Reddy, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave Ste 220, Vancouver, WA 98664 Phone: 360-882-2778 | |
Dr. David Steiger, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 505 Ne 87th Ave Ste 301, Vancouver, WA 98664 Phone: 360-514-7374 Fax: 360-514-7384 | |
Phillip M Cullison Bonner, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2211 Ne 139th St, Vancouver, WA 98686 Phone: 360-487-1000 | |
Louise M Schultz, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave, Vancouver, WA 98664 Phone: 360-882-2778 | |
Marissa Krienke, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 700 Ne 87th Ave Ste And240, Vancouver, WA 98664 Phone: 360-882-2778 | |
Joel David Mclarry, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave, Suite 210, Vancouver, WA 98664 Phone: 360-882-2778 | |
Dr. Samuel Everett George, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 19005 Se 34th St Bldg 3, Vancouver, WA 98683 Phone: 360-726-6720 Fax: 360-726-6729 |